UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

Rhea-AI Summary

UNITY Biotechnology (Nasdaq:UBX) is set to host a program update on its lead therapeutic UBX1325 for age-related diseases on November 1, 2022. The session features retinal expert Dr. Arshad M. Khanani, highlighting advancements in treatments aimed at senescent cells to combat aging-related conditions. This update signifies a pivotal moment in the company’s ongoing efforts to revolutionize therapies for ophthalmologic and neurological diseases.

Positive

• Scheduled update on lead program UBX1325, indicating progress in drug development.
• Engagement with expert Dr. Arshad M. Khanani to discuss innovations.

Negative

• None.

Program Update with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, to be held on Tuesday, November 1 at 5:00 a.m. PT/8:00 a.m. ET

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a program update to discuss its lead program in UBX1325 on Tuesday, November 1, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert and key opinion leader Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates.

The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

Media Contact
Evoke Canale
Katherine Smith
Katherine.Smith@evokegroup.com

FAQ

What is the purpose of UNITY's UBX1325 program update?

The program update aims to discuss advancements in UNITY's lead therapeutic, UBX1325, targeting age-related diseases.

When will the program update for UBX1325 take place?

The program update is scheduled for November 1, 2022, at 5:00 a.m. PT/8:00 a.m. ET.

Who is presenting at the UNITY program update?

Dr. Arshad M. Khanani, a retinal expert, will present during the program update.

How can investors access the UNITY program update?

Investors can access the live webcast on UNITY's website in the 'Investors and Media' section.

What potential impact could the UBX1325 program have on the market?

If successful, UBX1325 could transform treatment options for age-related diseases, potentially influencing market positioning.